Safety and Efficacy of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma
Latest Information Update: 11 Jan 2021
At a glance
- Drugs Cytarabine (Primary) ; Dexamethasone (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Ibrutinib (Primary) ; Rituximab (Primary) ; Temozolomide (Primary)
- Indications B-cell lymphoma; CNS cancer; Diffuse large B cell lymphoma; Marginal zone B-cell lymphoma; Plasmablastic lymphoma
- Focus Adverse reactions; Therapeutic Use
- 11 Jan 2021 New trial record
- 08 Dec 2020 Preliminary results (n=16; as of Jul 2020) presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.